VKTX – Viking Therapeutics, Inc.
Viking Therapeutics, Inc.VKTX
$32.68Name : Viking Therapeutics, Inc.
Sector : Healthcare
Industry: Biotechnology
Mark. Cap: $3,674,702,592.00
EPSttm : -1.54
Viking Therapeutics, Inc.
$32.68
0.34%$0.11Float Short %
26.22
Margin Of Safety %
Put/Call OI Ratio
0.28
EPS Next Q Diff
-0.16
EPS Last/This Y
-1.38
EPS This/Next Y
-0.56
Price
32.68
Target Price
89.95
Analyst Recom
1.21
Performance Q
14.21
Relative Volume
0.94
Beta
0.67
Ticker: VKTX
of 1
| Date | Symbol | Last | P/C OI | P/C Vol | Total OI |
|---|---|---|---|---|---|
| 2025-07-04 | VKTX | 28.15 | 0.24 | 0.17 | 229904 |
| 2025-07-07 | VKTX | 27.52 | 0.25 | 0.33 | 213630 |
| 2025-07-08 | VKTX | 30.19 | 0.26 | 0.15 | 219990 |
| 2025-07-09 | VKTX | 30.44 | 0.26 | 0.26 | 229099 |
| 2025-07-10 | VKTX | 31.21 | 0.26 | 0.38 | 232747 |
| 2025-07-11 | VKTX | 31.1 | 0.27 | 0.24 | 237532 |
| 2025-07-14 | VKTX | 31.62 | 0.27 | 0.33 | 220755 |
| 2025-07-15 | VKTX | 30.69 | 0.28 | 0.18 | 224946 |
| 2025-07-16 | VKTX | 31.64 | 0.28 | 0.19 | 227788 |
| 2025-07-17 | VKTX | 32.08 | 0.28 | 0.14 | 231531 |
| 2025-07-18 | VKTX | 31.99 | 0.28 | 0.21 | 237133 |
| 2025-07-21 | VKTX | 31.93 | 0.28 | 0.20 | 210512 |
| 2025-07-22 | VKTX | 32.1 | 0.29 | 0.66 | 220795 |
| 2025-07-23 | VKTX | 33.39 | 0.27 | 0.27 | 222799 |
| 2025-07-24 | VKTX | 33.46 | 0.29 | 0.24 | 235401 |
| 2025-07-25 | VKTX | 34.42 | 0.29 | 0.37 | 245649 |
| 2025-07-28 | VKTX | 33.19 | 0.29 | 0.30 | 227105 |
| 2025-07-29 | VKTX | 32.89 | 0.29 | 0.26 | 234906 |
| 2025-07-30 | VKTX | 33.7 | 0.29 | 0.25 | 237193 |
| 2025-07-31 | VKTX | 32.58 | 0.29 | 0.18 | 240928 |
| 2025-08-01 | VKTX | 32.67 | 0.28 | 0.36 | 245296 |
| Date | Symbol | Last | P/C OI | P/C Vol | Total OI |
Current Page1 of 1
of 1
| Date | Ticker | Price | Current Quarter Growth Estimate | EBIT Estimation | Average EPS Estimate Current Year |
|---|---|---|---|---|---|
| 2025-07-04 | VKTX | 28.19 | -120.3 | -64.9 | -1.84 |
| 2025-07-07 | VKTX | 27.52 | -120.3 | -52.0 | -1.84 |
| 2025-07-08 | VKTX | 30.19 | -120.3 | -90.7 | -1.84 |
| 2025-07-09 | VKTX | 30.40 | -120.3 | -61.7 | -1.84 |
| 2025-07-10 | VKTX | 31.29 | -120.3 | -68.6 | -1.84 |
| 2025-07-11 | VKTX | 31.11 | -120.3 | -66.8 | -1.84 |
| 2025-07-14 | VKTX | 31.63 | -120.3 | -64.6 | -1.84 |
| 2025-07-15 | VKTX | 30.70 | -120.3 | -50.6 | -1.84 |
| 2025-07-16 | VKTX | 31.63 | -120.3 | -68.8 | -1.84 |
| 2025-07-17 | VKTX | 32.07 | -120.3 | -63.8 | -1.84 |
| 2025-07-18 | VKTX | 32.01 | -120.3 | -58.9 | -1.84 |
| 2025-07-21 | VKTX | 31.95 | -120.3 | -59.0 | -1.84 |
| 2025-07-22 | VKTX | 32.08 | -120.3 | -60.9 | -1.84 |
| 2025-07-23 | VKTX | 33.40 | -120.3 | -71.8 | -1.84 |
| 2025-07-24 | VKTX | 33.50 | -120.3 | -60.4 | -1.84 |
| 2025-07-25 | VKTX | 34.42 | -120.3 | -27.1 | -1.84 |
| 2025-07-28 | VKTX | 33.26 | -211.8 | -87.0 | -2.40 |
| 2025-07-29 | VKTX | 32.91 | -211.8 | -96.9 | -2.40 |
| 2025-07-30 | VKTX | 33.71 | -209.3 | -110.1 | -2.39 |
| 2025-07-31 | VKTX | 32.57 | -209.3 | -86.9 | -2.39 |
| 2025-08-01 | VKTX | 32.68 | -209.3 | -101.8 | -2.39 |
| Date | Ticker | Price | Current Quarter Growth Estimate | EBIT Estimation | Average EPS Estimate Current Year |
Current Page1 of 1
of 1
| Date | Ticker | Insider Transactions | Institutional Transactions | Float Short |
|---|---|---|---|---|
| 2025-07-04 | VKTX | -9.11 | -5.22 | 26.13 |
| 2025-07-07 | VKTX | -1.02 | -5.27 | 26.13 |
| 2025-07-08 | VKTX | -1.01 | -5.27 | 26.13 |
| 2025-07-09 | VKTX | -1.01 | -5.27 | 26.13 |
| 2025-07-10 | VKTX | -1.01 | -5.27 | 26.13 |
| 2025-07-11 | VKTX | -1.01 | -5.27 | 26.30 |
| 2025-07-14 | VKTX | -1.01 | -5.24 | 26.30 |
| 2025-07-15 | VKTX | -1.01 | -5.24 | 26.30 |
| 2025-07-16 | VKTX | -1.01 | -5.24 | 26.30 |
| 2025-07-17 | VKTX | -1.01 | -5.24 | 26.30 |
| 2025-07-18 | VKTX | -1.01 | -5.24 | 26.30 |
| 2025-07-21 | VKTX | -1.01 | -5.10 | 26.30 |
| 2025-07-22 | VKTX | -1.01 | -5.10 | 26.30 |
| 2025-07-23 | VKTX | -1.01 | -5.10 | 26.30 |
| 2025-07-24 | VKTX | -1.01 | -5.10 | 26.30 |
| 2025-07-25 | VKTX | -1.01 | -5.10 | 26.25 |
| 2025-07-28 | VKTX | -1.01 | -4.88 | 26.22 |
| 2025-07-29 | VKTX | -1.01 | -4.88 | 26.22 |
| 2025-07-30 | VKTX | -1.01 | -4.88 | 26.22 |
| 2025-07-31 | VKTX | -1.01 | -4.88 | 26.22 |
| 2025-08-01 | VKTX | -1.01 | -4.88 | 26.22 |
| Date | Ticker | Insider Transactions | Institutional Transactions | Float Short |
Current Page1 of 1
Last Quarter Act. EPS
-0.58
Avg. EPS Est. Current Quarter
-0.68
Avg. EPS Est. Next Quarter
-0.74
Insider Transactions
-1.01
Institutional Transactions
-4.88
Beta
0.67
Average Sales Estimate Current Quarter
Average Sales Estimate Next Quarter
Fair Value
Quality Score
12
Growth Score
18
Sentiment Score
7
Actual DrawDown %
67.1
Max Drawdown 5-Year %
-78.9
Target Price
89.95
P/E
Forward P/E
PEG
P/S
P/B
4.61
P/Free Cash Flow
EPS
-1.53
Average EPS Est. Cur. Y
-2.39
EPS Next Y. (Est.)
-2.96
Target Price Estimates Raised
Target Price Estimates Lowered
Profit Margin
Relative Volume
0.94
Return on Equity vs Sector %
-45.3
Return on Equity vs Industry %
-26.7
EPS 1 7Days Diff
-0.5
EPS 1 30Days Diff
-0.55
EBIT Estimation
-101.8
Viking Therapeutics, Inc.Sector: Healthcare
Industry: Biotechnology
Employees: 48
Viking Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development of novel therapies for metabolic and endocrine disorders. The company's lead drug candidate is VK2809, an orally available tissue and receptor-subtype selective agonist of the thyroid hormone receptor beta (TRß), which is in Phase IIb clinical trials to treat patients with biopsy-confirmed non-alcoholic steatohepatitis, as well as NAFLD. It develops VK5211, an orally available non-steroidal selective androgen receptor modulator that is in Phase II clinical trials for the treatment of patients recovering from non-elective hip fracture surgery; VK0612, an orally available Phase IIb-ready drug candidate for type 2 diabetes; VK2735, a novel dual agonist of the glucagon-like peptide, which is in Phase 1 SAD/MAD clinical trial, and VK0214, an orally available tissue and receptor-subtype selective agonist of the TRß for X-linked adrenoleukodystrophy. The company was incorporated in 2012 and is headquartered in San Diego, California.
stock quote shares VKTX – Viking Therapeutics, Inc. Stock Price stock today
news today VKTX – Viking Therapeutics, Inc. stock forecast ,stock prediction 2023 2024 2025
marketwatch VKTX – Viking Therapeutics, Inc. yahoo finance google finance
stock history VKTX – Viking Therapeutics, Inc. invest stock market
stock prices VKTX premarket after hours
ticker VKTX fair value insiders trading